With more than 4,142 votes cast, the readers of this blog have chosen the top 12 finalists for the Stem Cell Person of the Year Award for 2014 from the 27 nominees. You can see the final vote tallies at left. The votes came from more than 50 countries with some interesting geographic patterns (I […]
Diverse Stem Cell Person of the Year 2014 Award Finalists Read More »
With one week left to vote to pick the top 12 finalists for the Stem Cell Person of the Year 2014 Award, we have more than 2,800 votes in so far. From the top 12 vote-getters, I will choose the winner. This is the third year of this award. I self-fund this award out of
Stem Cell Person of the Year Award 2014 Voting: Who Will Be Finalists? Read More »
There has been considerable discussion about the whether the media hyped the recent Harvard stem cells for diabetes paper (see top 10 takeaways of that paper). I believe that this was greatly hyped. This Harvard publication reported production of insulin-secreting cells from human embryonic stem cells (hESC). Newspapers around the world widely exaggerated the potential impact
Stem cells for Diabetes: the danger of the word ‘cure’ Read More »
The idea of using stem cells for treat Type I Diabetes is very promising and could have huge practical impact. Real progress has been achieved toward this goal over the last decade. In perhaps another decade there might be a validated treatment. A new stem cell paper has just come out in Cell from Harvard in this
Takeaways From Harvard Stem Cells for Diabetes Paper Read More »
Nominations have closed and we have more than two dozen nominations for Stem Cell Person of the Year 2014. It’s an exciting, diverse group including some news faces as well as nominees from years past as well. Happy Stem Cell Day! You can now vote for your choice for the top finalists in the poll
Stem Cell Person of the Year 2014 Award: Vote To Choose 12 Finalists Read More »
How do “drugs” influence stem cells? Here’s the straight dope. Those of us in the trenches of the stem cell research field spend an inordinate amount of time talking about stem cell treatments (i.e. you inject stem cells into a person hoping for a medical benefit), and far too little time discussing endogenous stem cells.
These are your stem cells on drugs…any questions? Read More »
Some diverse new stem cell papers worth a peek this weekend? Direct reprogramming hits crest: Generation of Multipotent Induced Neural Crest by Direct Reprogramming of Human Postnatal Fibroblasts with a Single Transcription Factor, Cell Stem Cell Hormone receptors in prostate cancer cells versus stem cells: Concise Review: Androgen Receptor Differential Roles in Stem/Progenitor Cells Including Prostate, Embryonic, Stromal,
5 new cool stem cell papers worth a look for weekend reading Read More »
The BioTime subsidiary, Asterias, has received FDA approval for a combined Phase I/IIa clinical trial of OPC1 for treating spinal cord injury. BioTime (BTX) and Asterias (ASTY) have picked up the portfolio of the former Geron clinical trial using oligodendrocyte precursor cells (OPC). Asterias also acquired a second element from Geron in the form of a lung
Interview with Jane Lebkowski on Asterias FDA-approved Stem Cell Trial Read More »
Type 1 Diabetes is a huge global problem. Where are the solutions that would compliment or replace insulin therapy for diabetics? There haven’t been too many that have gotten very far, which makes the news of a potential stem cell-based therapy moving along in the pipeline all the more exciting. ViaCyte (see more posts here,
Great News: FDA Nod For ViaCyte IND of Diabetes Stem Cell-Based Product Read More »
This post is a tribute to the late Dr. Yoshiki Sasai (笹井芳樹). If you would like your name added to this tribute please let me know. You are also welcome to add your own tributes in the comments. In an era when the emerging field of regenerative medicine is just beginning to take wing, we
Stem Cell Community Tribute to Yoshiki Sasai (笹井芳樹) Read More »